Core Insights - Traws Pharma has completed a clinical analysis of ratutrelvir, showing it has a differentiated profile compared to PAXLOVID® with fewer adverse events and no viral rebounds, while achieving equivalent time to sustained symptom resolution [1][4] - The company is also advancing tivoxavir marboxil, which has shown increased exposure in pre-clinical studies and is being developed as a once-monthly oral tablet for influenza prevention [5][7] Ratutrelvir Update - The Phase 2 study of ratutrelvir involved 90 patients and compared its efficacy and safety against PAXLOVID®, with a specific focus on patients ineligible for ritonavir-boosted therapies [2][3] - Patients receiving ratutrelvir reported fewer treatment-related adverse events (10% vs. 23.3% for PAXLOVID®) and quicker symptom resolution [3] Clinical Benefits of Ratutrelvir - Ratutrelvir may provide significant benefits for a broader range of patients, particularly those unable to receive ritonavir-boosted therapy, with a favorable tolerability profile and absence of viral rebound events [4] - The drug's potential to reduce post-acute sequelae of SARS-CoV-2 infection (Long COVID) is highlighted, suggesting it may enable earlier and more complete viral clearance [4] Tivoxavir Marboxil Update - Traws Pharma is progressing tivoxavir marboxil as a potential best-in-class CAP-dependent endonuclease inhibitor for seasonal influenza, with a single oral tablet formulation showing a 30% increase in exposure compared to previous formulations [5][7] - The company plans to conduct a healthy volunteer study in Australia to confirm the extended exposure and potentially advance to a Seasonal Human Influenza Virus Prophylaxis Challenge Study [7] Regulatory Considerations - The FDA has placed the US IND for tivoxavir marboxil on clinical hold due to concerns regarding mutagenicity data, with formal communication expected by March 16, 2026 [8] - Despite the clinical hold, ongoing and planned studies outside the United States are not directly impacted, and the company is working to address the FDA's concerns [8]

Core Insights - Expert Systems Inc. continues to support Traws Pharma as it initiates Phase 2 clinical studies of Ratutrelvir (TRX01), an oral antiviral for newly diagnosed COVID-19 patients [1][5] Company Overview - Expert Systems Inc. is a life sciences accelerator focused on advancing precision therapeutics through an AI/ML-enabled platform that integrates drug design, predictive pharmacology, and regulatory strategy [6][7] Product Development - Ratutrelvir (TRX01) shows broad-spectrum in vitro activity against various SARS-CoV-2 strains and has a unique formulation that does not require ritonavir, thus avoiding drug-drug interactions that affect about 20% of COVID patients [3][4] - In Phase 1 studies, a daily oral dose of 600 mg maintained plasma concentrations approximately 13 times above the effective concentration (EC50) for the entire 10-day course, with trough levels above EC90, crucial for preventing viral rebound [4][5] - The Phase 2 program includes a non-inferiority trial against PAXLOVID® and a trial for populations ineligible for PAXLOVID®, addressing a significant unmet need [8] Strategic Collaboration - Expert Systems will provide ongoing strategic, scientific, and technological support as Ratutrelvir progresses through human efficacy studies, highlighting its capability to de-risk innovation and accelerate clinical translation [5]

Core Viewpoint - Traws Pharma is advancing the development of ratutrelvir, a ritonavir-free treatment for COVID-19, through two Phase 2 trials aimed at evaluating its safety and efficacy compared to PAXLOVID®, with top-line data expected by the end of 2025 [1][2][3]. Group 1: Company Overview - Traws Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for respiratory viral diseases, including COVID-19 and Long COVID [6]. - The company integrates antiviral drug development with medical intelligence and regulatory strategy to address challenges in treating viral diseases [6]. Group 2: Product Development - Ratutrelvir is an investigational oral small molecule Mpro (3CL protease) inhibitor designed to treat SARS-CoV-2 without the need for ritonavir, potentially avoiding drug-drug interactions [3]. - Preclinical and Phase 1 studies indicate that ratutrelvir maintains target blood plasma levels significantly above the effective concentration, which may reduce the likelihood of clinical rebound and Long COVID [3]. Group 3: Market Context - In Q2 2025, Pfizer reported $427 million in sales for PAXLOVID®, marking a 70% increase from the same period the previous year, highlighting the ongoing demand for effective COVID-19 treatments [2]. - The rapid emergence of new viral variants, such as NB.1.8.1, which now accounts for 40% of COVID cases, underscores the need for effective antiviral therapies [2]. Group 4: Clinical Trials - The first trial will compare ratutrelvir against PAXLOVID® in newly diagnosed COVID patients, while a second trial will focus on PAXLOVID®-ineligible patients, a vulnerable group with limited treatment options [1][2]. - Results from both Phase 2 studies are anticipated by the end of 2025, which could provide critical proof-of-concept data for ratutrelvir [2].